DCDavid Cho

David Cho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Cho has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dantrolene use across surgical and medical care at Mayo Clinic from 2010 to 2024: Indications, frequency, and value for identifying malignant hyperthermia

    by David Cho, Toby N. Weingarten, Juraj Sprung, Aurelia Zodl, Martin J. Ryll, Tracy E. Harrison

    Dantrolene is the definitive treatment for malignant hyperthermia (MH), a rare and life-threatening disorder. This retrospective study aimed to achieve two objectives: (1) to characterize the indications and frequency of dantrolene administration in both medical and surgical settings, and (2) to evaluate whether perioperative dantrolene may serve as a surrogate marker for identifying MH cases. Using pharmacy records, we identified hospitalized patients who received dantrolene between 2010 and 2024. Each recipient underwent a chart review to examine the clinical context of dantrolene administration. A total of 1,199,450 inpatient pharmacy records were reviewed, revealing 118 patients who received dantrolene, resulting in an incidence rate of 1 in 10,165 hospital admissions (95% CI: 1 in 8,488 to 1 in 12,280). Among these, 87 patients (74%) received oral dantrolene: 84 for chronic spasticity, two for neuroleptic malignant syndrome, and one as preoperative prophylaxis due to a history of MH. The remaining 31 patients (26%) received intravenous dantrolene. Seventeen patients received perioperative dantrolene for suspected MH; of these, nine cases (53%) were subsequently clinically confirmed as MH. Based on these findings and the total number of surgical procedures involving general anesthesia (n=885,127), the estimated prevalence of MH following general anesthesia was calculated to be 1 in 98,328 exposures (95% CI: 1 in 51,813 to 1 in 215,054). Dantrolene was administered at an approximate rate of 1 per 10,000 hospital admissions, primarily in oral formulation for chronic spasticity. Among the patients who received perioperative dantrolene, approximately half were confirmed to have MH, resulting in an estimated MH prevalence of 1 in 100,000 patients exposed to general anesthesia.


  • Open Access

    Implantable peripheral nerve stimulation for chronic pain: a systematic review and meta-analysis of analgesic outcomes up to 24 months

    by Ryan S D’sOuza, Yeng F Her, Mahmoud Morsi, Hunter Soleymani, Dylan Banks, Theodore A Miclau, Eleena Ekhtiari, David Cho, Larry Prokop, Nasir Hussain

    Background: Peripheral nerve stimulation (PNS) has emerged as a promising neurostimulation modality, yet its effectiveness and durability for chronic pain remain uncertain. We conducted a systematic review and meta-analysis to evaluate changes in pain intensity following implantable PNS therapy. Methods: Eligible studies included adults (≥18 years) with chronic pain treated with an implantable PNS system, and pain intensity was assessed at baseline and follow-up time points. The primary outcome was change in pain intensity from baseline to 6 months after PNS implantation. Secondary outcomes included changes in pain intensity at 3, 12 and 24 months after PNS implantation. Standardized mean differences (Hedges’ g ) were pooled using a random-effects model. Results: A total of 106 studies comprising 9272 patients were included. PNS was associated with large, statistically significant reductions in pain intensity from baseline to all time points: 3 months (Hedges’ g 2.92; 95% CI 2.62 to 3.21), 6 months (Hedges’ g 3.08; 95% CI 2.68 to 3.48), 12 months (Hedges’ g 2.68; 95% CI 2.30 to 3.05) and 24 months (Hedges’ g 2.08; 95% CI 1.68 to 2.48) (all p<0.001). However, the certainty of evidence as assessed by the Grading of Recommendations Assessment, Development and Evaluation criteria was rated as low for the primary outcome, due to pooling from observational studies, risk of bias, and heterogeneity (statistical, clinical and methodological). Subgroup analyses revealed no differences by study design or device type, while smaller effect sizes were reported in industry-funded studies and those with declared conflicts of interest. The largest effect sizes were observed in pelvic and upper extremity pain, whereas the smallest in truncal pain. Conclusion: Implantable PNS provides persistent and clinically meaningful analgesia for chronic pain, with benefits sustained up to 24 months. These findings support broader clinical adoption and provide evidence to inform pay0r coverage and policy decisions.


  • Shared decision‐making for patients with vaccine‐related concerns of blood transfusion: A single institution experience

    by David J. Cho, Allan M. Klompas, Jessica A. Gonzalez, Jamie L. Petsch, Jen M. Burt, Daryl J. Kor, Jeffrey L. Winters, Camille M. van Buskirk, Matthew A. Warner

    Background: Some patients express concerns regarding receipt of allogeneic blood transfusions from donors potentially vaccinated against SARS‐CoV‐2 (COVID‐19). However, limited information exists about patients' expression of these concerns or how to address them during the blood transfusion consent process. In this study, we describe our experience of working collaboratively with patients with vaccine‐related transfusion concerns prior to elective surgery, summarizing treatment decisions and clinical outcomes.Study Design and Methods: This observational descriptive study includes patients seen in our Bloodless Medicine and Surgery clinic between June 2022 and June 2024 for vaccine‐related transfusion concerns prior to elective surgery. A shared decision‐making framework was employed to foster conversation, share information, provide reassurance, reconcile conflict, and match preferences with available care options. Patient characteristics, treatment decisions, and surgical outcomes were reviewed and summarized.Results: Thirty‐five patients were included, with median (1st, 3rd quartile) age of 61 (53, 69) years. Cardiac surgery was the most common type of surgery (29%). Twelve patients (34%) were anemic preoperatively, and all received preoperative treatment. After discussion with a Bloodless Medicine specialist, 24 (68.6%) decided to consent to the use of all blood products, 5 (14.3%) accepted only red blood cells, and 6 (17.1%) declined all blood products. Among 28 patients undergoing surgery, only 4 (14%) received allogeneic transfusion perioperatively.Conclusion: Many patients concerned about the vaccination status of blood donors may ultimately consent to allogeneic blood products after shared decision‐making with a Bloodless Medicine specialist, highlighting the importance of patient empowerment and collaborative care.


  • Crowdsourcing the Perception of the Bicoronal Scar in Open Cranial Vault Reconstruction

    by Tulsi Roy, Julia Chavez, David Cho, Rafal Sobota, Russell R. Reid

    Purpose: Within open cranial vault reconstruction (CVR) for craniosynostosis, efforts have been directed at minimizing the bicoronal scar, which contributes to increased patient stigmatization and decreased parental satisfaction. To understand these esthetic considerations across multiple centers, we evaluated demographic and clinical determinants of patient scar self-consciousness, parental scar satisfaction, and parental satisfaction with their children’s overall medical and surgical care. Methods: A 25-item questionnaire was distributed within an 18 500-member craniosynostosis parental online support group. Parents were asked to grade patient scar self-consciousness, parental scar satisfaction, and parental satisfaction with their children’s overall care on a 10-point Likert scale. A t-test and linear regression were performed for binary and continuous variables. Results: Of 838 responses, 516 met inclusion criteria. 32% of patients had visible scar alopecia and 25% of respondents reported their child’s hair is deliberately styled to disguise the scar. 2% of patients underwent scar revision. Older age, complications, ongoing symptoms, and increased number of surgeries were negatively associated with parental scar satisfaction, patient self-consciousness, and parental satisfaction with overall management. Ethnicity and hair texture were not associated with patient self-consciousness or parental satisfaction with care. Incision type (zig-zag/wavy compared to straight bicoronal incisions) showed no significant difference in subjective outcomes measures or rates of external stigmatizing behavior between the 2 groups. Conclusions: Bicoronal scarring has complex and multifaceted psychosocial effects. Advanced age, complications, ongoing symptoms, and increased number of surgeries are key determinants of patient and parent satisfaction, though parental esthetic satisfaction may be more sensitive to external stigmatizing behavior. This study calls for a reappraisal of conventional teaching regarding the impact of incision design. While craniofacial morphology, neurological development, and social functioning may be more foundational to overall patient and parent satisfaction, the esthetic value of the bicoronal scar should not be undervalued.


  • Open Access

    MetAP2 inhibition reduces food intake and body weight in a ciliopathy mouse model of obesity

    by Tana S. Pottorf, Micaella P. Fagan, Bryan F. Burkey, David J. Cho, James E. Vath, Pamela V. Tran

    The ciliopathies Bardet-Biedl syndrome and Alström syndrome are genetically inherited pleiotropic disorders with hyperphagia and obesity as primary clinical features. Methionine aminopeptidase 2 inhibitors (MetAP2i) have been shown in preclinical and clinical studies to reduce food intake, body weight, and adiposity. Here, we investigated the effects of MetAP2i administration in a mouse model of ciliopathy produced by conditional deletion of the Thm1 gene in adulthood. Thm1 conditional knockout (cko) mice showed decreased hypothalamic proopiomelanocortin expression as well as hyperphagia, obesity, metabolic disease, and hepatic steatosis. In obese Thm1 -cko mice, 2-week administration of MetAP2i reduced daily food intake and reduced body weight 17.1% from baseline (vs. 5% reduction for vehicle). This was accompanied by decreased levels of blood glucose, insulin, and leptin. Further, MetAP2i reduced gonadal adipose depots and adipocyte size and improved liver morphology. This is the first report to our knowledge of MetAP2i reducing hyperphagia and body weight and ameliorating metabolic indices in a mouse model of ciliopathy. These results support further investigation of MetAP2 inhibition as a potential therapeutic strategy for ciliary-mediated forms of obesity.